Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 30, 2003
Business Overview: Illumina develops next-generation tools for large-scale genetic analysis, including oligonucleotides, SNP genotyping services, and genotyping systems. The company is in an early stage of commercialization with a focus on life sciences and pharmaceutical markets.
Key Financial Metrics
| Metric (in thousands) | Q1 2003 | Q1 2002 |
|---|---|---|
| Total Revenue | $4,276 | $1,269 |
| Net Loss | $(8,960) | $(8,667) |
| Net Loss Per Share (Basic/Diluted) | $(0.28) | $(0.28) |
| Cash and Cash Equivalents | $4,879 | $10,417 |
| Total Investments (Available for Sale) | $43,024 | N/A |
| Restricted Cash and Investments | $12,482 | $12,530 |
| Total Current Assets | $66,170 | $72,819 |
| Total Liabilities | $51,333 | $49,153 |
| Stockholders' Equity | $63,886 | $71,744 |
| Long-Term Debt (less current) | $25,273 | $25,367 |
| Accrued Litigation Judgment | $8,241 | $8,052 |
Liquidity: As of March 30, 2003, the company held approximately $60.4 million in cash, cash equivalents, and investments (including restricted funds). Management expects these resources to fund operations for 18 to 24 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 237% to $4.3 million, driven by the first sale of a production-scale SNP genotyping system ($1.4 million product revenue) and the launch of SNP genotyping services ($1.9 million service revenue).
- Operating Expenses: Total operating expenses rose to $13.3 million from $10.3 million. Selling, general, and administrative (SG&A) expenses increased significantly to $4.6 million (from $1.6 million) due to legal fees related to litigation and expanded sales/marketing efforts.
- Research & Development: R&D expenses decreased to $5.7 million (from $7.1 million) as the company shifted resources from development to commercialization of the genotyping system.
- Cash Flow: Net cash used in operating activities improved to $5.0 million (from $6.6 million used). Investing activities provided $7.6 million in cash (vs. $13.4 million used previously) due to maturities of investment securities.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook
Management anticipates continued net losses and negative cash flow for the foreseeable future. Significant increases in revenue are required to achieve profitability. The company plans to expand sales and marketing infrastructure globally (Europe and Japan) and expects operating expenses to accelerate.
Material Risks and Contingencies
- Applied Biosystems Litigation: A significant legal dispute exists with Applied Biosystems regarding a joint development agreement. Applied Biosystems alleges patent infringement and breach of contract, seeking $30 million in damages and an injunction. Illumina has countersued for breach of contract and fraud. The outcome is uncertain and could materially adversely affect the business.
- Employment Litigation: The company is appealing a $7.7 million judgment from a termination-of-employment lawsuit. Interest on this judgment is accruing, and approximately $12.5 million of marketable securities are restricted as collateral for a surety bond.
- Deferred Revenue: $10 million in non-refundable research funding from Applied Biosystems remains classified as deferred revenue until the legal status of the collaboration is resolved.
- Capital Needs: While current funds are expected to last 18-24 months, the company may require additional funding sooner if commercialization efforts are delayed or legal costs increase. Future equity financing could be dilutive.
Investor Verification Checklist
- Legal Exposure: Verify the current status of the patent infringement and breach of contract lawsuits with Applied Biosystems and the appeal of the $7.7 million employment judgment.
- Revenue Sustainability: Assess whether the $4.3 million revenue run rate is sustainable given the reliance on large, individual transactions (e.g., the first genotyping system sale).
- Liquidity Constraints: Confirm the impact of the $12.5 million restricted cash/investments on operational liquidity.
- Deferred Revenue: Monitor the resolution of the Applied Biosystems dispute to determine if the $10 million deferred revenue will ever be recognized.
- Burn Rate: Evaluate the trajectory of SG&A expenses, which have tripled year-over-year, against the pace of revenue growth.